{"prompt": "['Carboxymethyleellulose and Carbomer', '209510', 'Clinical Protocol v1.0', '10.4.1', 'Reporting of an Adverse Event', '41', '10.4.2', 'Reporting of a Serious Adverse Event', '41', '10.5', 'Evaluating Adverse Events', '42', '10.5.1', 'Assessment of Intensity', '42', '10.5.2', 'Assessment of Causality', '43', '10.6', 'Follow-up of Adverse Events', '43', '10.7', 'Withdrawal Due to an Adverse Event', '44', '10.7.1', \"Sponsor's Reporting Requirements to Regulatory Authorities and\", 'Ethics Committees', '44', '10.8 Pregnancy', '44', '10.8.1', 'Time Period for Collecting Pregnancy Information', '44', '10.8.2', 'Action to be Taken if Pregnancy Occurs', '45', '10.9', 'Definition of and Procedure for Reporting Medical Device Incidents', '45', '10.9.1', 'Definition of an Incident', '45', '10.9.2', 'Reporting of Incidents and Malfunctions', '46', '10.9.3', 'Follow-up of Medical Device Incidents', '47', '10.9.4', 'Regulatory and Ethics Reporting Requirements for Incidents', '47', '11 DATA MANAGEMENT', '47', '11.1', 'Case Report Form', '48', '11.2', 'Data Handling', '48', '11.2.1', 'Data Queries', '48', '11.3', 'Processing Patient Reported Outcomes', '49', '12 STATISTICAL CONSIDERATIONS AND DATA ANALYSES', '49', '12.1', 'Sample Size Determination', '49', '12.2', 'Statistical Methods and Analytical Plan', '49', '12.2.1', 'Definition of Analysis Populations', '50', '12.2.2', 'Exclusion of Data from Analysis', '50', '12.2.3', 'Demographic and Baseline Characteristics', '50', '12.2.4', 'Study Drug/Product Compliance', '50', '12.2.5', 'Primary Analysis', '50', '12.2.6', 'Secondary Analyses', '51', '12.2.7', 'Safety Analysis', '51', '12.2.8', 'Handling of Dropouts and Missing Data', '51', '12.2.9', 'Interim Analysis', '51', '13 STUDY GOVERNANCE CONSIDERATIONS', '51', '13.1', 'Quality Control', '51', '13.2', 'Quality Assurance', '52', '13.3', 'Regulatory and Ethical Considerations', '52', '13.3.1', 'Institutional Review Board/Ethics Committee', '52', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 6 of 65']['Carboxymethyleellulose and Carbomer', '209510', 'Clinical Protocol v1.0', '13.3.2', 'Ethical Conduct of the Study', '52', '13.3.3', 'Subject Information and Consent', '53', '13.3.4', 'Subject Recruitment', '53', '13.3.5', 'Reporting of Safety Issues and Serious Breaches of the Protocol or', 'ICH GCP', '53', '13.4', 'Posting of Information on Publicly Available Clinical Trial Registers', '54', '13.5', 'Provision of Study Results to Investigators', '54', '13.6', 'Records Retention', '54', '13.7', 'Conditions for Terminating the Study', '55', '14 REFERENCES', '55', '15 APPENDIX', '56', '15.1', 'ABBREVIATIONS', '56', '15.2', 'Application Instructions:', '58', '15.3', 'Example of the Gum-Comfort Questionnaire', '59', '15.4 Example of the Oral Health Impact Profile for Edentulous Patients (OHIP-', 'Edent) Questionnaire', '60', '15.5', 'Example of the General Oral Health Assessment Index (GOHAI)', 'Questionnaire', '63', '15.6', 'Example of the Product Sensory Questionnaire', '65', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 7 of 65']\n\n###\n\n", "completion": "END"}